Purpose Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or
marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated …

Related HLA-haploidentical blood or marrow transplantation (BMT) with high-dose
posttransplantation cyclophosphamide (PTCy) is being increasingly used because of its …

Although some reports have found an association between increasing HLA disparity
between donor and recipient and fewer relapses after allogeneic blood or marrow …

We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide
(Cy) to prevent graft rejection and graft-versus-host disease (GVHD) after outpatient …

Hematopoietic stem cell transplantation provides the only potential curative option in many
patients with hematological malignancies. Finding a suitably matched donor in a timely …

Allogeneic stem cell transplantation (SCT) from an HLA-haploidentical relative provides a
potentially curative treatment option for hematologic malignancies patients who lack a …

Composite endpoints that not only encompass mortality and relapse, but other critical post-
transplant events such as graft-versus-host disease, are being increasingly utilized to …

Purpose T-cell–replete grafts from haploidentical donors using post-transplantation
cyclophosphamide may represent a solution for patients who require allogeneic …

Outcomes of nonmyeloablative (NMA) haploidentical (haplo) blood or marrow transplant
(BMT) with post-transplantation cyclophosphamide (PTCy) using non–first-degree relatives …

Abstract Treatment of relapse after related HLA-haploidentical T cell–replete bone marrow
transplantation (haploBMT) with post-transplantation cyclophosphamide (PTCy) using …